Endocrine Abstracts

Introduction: Liraglutide has shown several benefits in diabetic patients, both in terms of glycemic profile and metabolic control. The objective of our work is to show the effects of liraglutide on the metabolic profile of obese T2D patients.

Materials and methods: This is a prospective study involving 31 obese T2D patients followed at the Department of Endocrinology and Metabolic Diseases CHU IBN ROCHD from January 2018 to December 2022. The data analysis was done with the Excel software in its 2021 version.

Results: The mean age was 49.44 years, Sex Ratio: M/F of: 1/4, the duration of diabetes was on average 12.17 years, the mean duration of treatment with liraglutide was 3 years. All our patients were obese with an average BMI of 39 kg/m2 and a waist circumference of 121 cm. All of our patients were unbalanced with an average Hb1c of 10%. The metabolic balance objectified dyslipidemia in 24 patients or 82.7% with a mean cholesterol level of 1.9 g / l, mean triglyceride of 1.47 g / l, mean HDL of 0.49 g / l and mean LDL level of 1.11 g / l. Arterial hypertension was objectified in 13 patients or 44.8% all monotherapy, hyperuricemia was objectified in 4 patients or 13.8% with an average uric acid level of 58.91 mg / l. The majority of patients or 75.8% were on insulins either in basal bolus or bed time regimen in combination with metformin and sulfonamide and 24.2% are on dual therapy metformin sulfonamide. After the introduction of liraglutide treatment, there was a decrease in BMI to 37.74 (−1.26), a decrease in waist circumference to 111.25 (−5.39), a decrease in Hba1c to 7.47 (− 2.53%), a decrease in uric acid to 55.33 (−3.58), an improvement in lipid profile with a decrease in LDL to 0.89 g / l (−0.22), a decrease in CT to 1.72 g / l (−0.18), a decrease in TG to 1.4 (−0.05) and an improvement in HDL to 0.52 (+0.03). Regarding the treatment of diabetes, 23.33% of our patients had benefited from insulin withdrawal.

Conclusion: Treatment with GLP-1 analogues offers a new therapeutic option of major interest in the management of type 2 diabetes.